Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
Across indications, both physicians and patients reported positive clinical outcomes and high levels of satisfaction with ABP 501 treatment, regardless of prior use of RP.
Authors
- James Piercy (ORCID: https://orcid.org/0000-0001-7015-1021)
- Waldemar Radziszewski (ORCID: https://orcid.org/0000-0001-5254-7436)
- Ran Jin (ORCID: https://orcid.org/0000-0002-0245-9187)
- Rachael Meadows (ORCID: https://orcid.org/0000-0001-9047-4733)
- Stanley Cohen (ORCID: https://orcid.org/0000-0002-9226-979X)
- Delphine Courmier (ORCID: https://orcid.org/0009-0003-4436-1537)
- James Haughton (ORCID: https://orcid.org/0000-0003-4089-5809)
- Emily J. Goddard (ORCID: https://orcid.org/0000-0002-1480-040X)
Institutions
- Amgen (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s40744-025-00755-9
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen